---
figid: PMC5871897__41698_2018_49_Fig8_HTML
figlink: /pmc/articles/PMC5871897/figure/Fig8/
number: Fig. 8
caption: 'KYA1797K as a potential strategy to overcome resistance to EGFR targeting
  drugs in CRC. a A schematic representation of several therapeutic agents targeting
  the EGFR-RAS-ERK pathway including EGFR antibody drug cetuximab, FTase (farnesyl
  transferase) inhibitor SCH66336, KRAS-G12C specific inhibitor ARS-853 and those
  targeting Wnt/β-catenin pathways, including the IWR-1 and XAV939 TNKS (tankyrase)
  inhibitors and KYA1797K targeting RGS-Axin. b Differences in the mode of actions
  of TNKS inhibitors and KYA1797K. Left: TNKS inhibitors indirectly target the destruction
  complex by inhibiting the TNKS-mediated Axin destabilization which may change the
  balance of the β-catenin destruction complex components. Right: KYA1797K directly
  targets the destruction complex by binding to Axin-RGS which enhances the formation
  of the β-catenin destruction complex leading to increased GSK3β activity without
  changing the stoichiometry of the β-catenin destruction complex. F, farnesylation;
  PAR, poly-ADP-ribosylation; Dotted line, not experimentally confirmed'
pmcid: PMC5871897
papertitle: Interaction between Wnt/β-catenin and RAS-ERK pathways and an anti-cancer
  strategy via degradations of β-catenin and RAS by targeting the Wnt/β-catenin pathway.
reftext: Woo-Jeong Jeong, et al. NPJ Precis Oncol. 2018;2:5.
pmc_ranked_result_index: '99415'
pathway_score: 0.9263774
filename: 41698_2018_49_Fig8_HTML.jpg
figtitle: KYA1797K as a potential strategy to overcome resistance to EGFR targeting
  drugs in CRC
year: '2018'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5871897__41698_2018_49_Fig8_HTML.html
  '@type': Dataset
  description: 'KYA1797K as a potential strategy to overcome resistance to EGFR targeting
    drugs in CRC. a A schematic representation of several therapeutic agents targeting
    the EGFR-RAS-ERK pathway including EGFR antibody drug cetuximab, FTase (farnesyl
    transferase) inhibitor SCH66336, KRAS-G12C specific inhibitor ARS-853 and those
    targeting Wnt/β-catenin pathways, including the IWR-1 and XAV939 TNKS (tankyrase)
    inhibitors and KYA1797K targeting RGS-Axin. b Differences in the mode of actions
    of TNKS inhibitors and KYA1797K. Left: TNKS inhibitors indirectly target the destruction
    complex by inhibiting the TNKS-mediated Axin destabilization which may change
    the balance of the β-catenin destruction complex components. Right: KYA1797K directly
    targets the destruction complex by binding to Axin-RGS which enhances the formation
    of the β-catenin destruction complex leading to increased GSK3β activity without
    changing the stoichiometry of the β-catenin destruction complex. F, farnesylation;
    PAR, poly-ADP-ribosylation; Dotted line, not experimentally confirmed'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - GIP
  - GRB2
  - FZD9
  - FZD3
  - LRP5
  - LRP6
  - FZD1
  - FZD8
  - DVL3
  - EGFR
  - FZD7
  - GSK3B
  - FZD2
  - FZD5
  - KRAS
  - FZD10
  - FZD4
  - FZD6
  - CTNNB1
  - NRAS
  - MAP2K1
  - MAP2K2
  - JTB
  - APC
  - ARAF
  - BRAF
  - HRAS
  - SOS2
  - AXIN1
  - AXIN2
  - SOS1
  - TNKS
  - DVL1
  - DVL2
  - CSNK1A1
  - RAF1
  - BTRC
  - PLAUR
  - Erlotinib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: GIP
  symbol: GIP
  source: hgnc_symbol
  hgnc_symbol: GIP
  entrez: '2695'
- word: Grb2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD9
  entrez: '8326'
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD3
  entrez: '7976'
- word: LRP5/6
  symbol: LRP5
  source: hgnc_symbol
  hgnc_symbol: LRP5
  entrez: '4041'
- word: LRP5/6
  symbol: LRP6
  source: hgnc_symbol
  hgnc_symbol: LRP6
  entrez: '4040'
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD1
  entrez: '8321'
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD8
  entrez: '8325'
- word: DVL
  symbol: DVL
  source: bioentities_symbol
  hgnc_symbol: DVL3
  entrez: '1857'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD7
  entrez: '8324'
- word: GSK3B
  symbol: GSK3B
  source: hgnc_symbol
  hgnc_symbol: GSK3B
  entrez: '2932'
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD2
  entrez: '2535'
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD5
  entrez: '7855'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD10
  entrez: '11211'
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD4
  entrez: '8322'
- word: FZD
  symbol: FZD
  source: bioentities_symbol
  hgnc_symbol: FZD6
  entrez: '8323'
- word: B.Catenin
  symbol: BCATENIN
  source: bioentities_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PAR
  symbol: PAR
  source: hgnc_alias_symbol
  hgnc_symbol: JTB
  entrez: '10899'
- word: APC
  symbol: APC
  source: hgnc_symbol
  hgnc_symbol: APC
  entrez: '324'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: SOS
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: Axin
  symbol: AXIN
  source: bioentities_symbol
  hgnc_symbol: AXIN1
  entrez: '8312'
- word: Axin
  symbol: AXIN
  source: bioentities_symbol
  hgnc_symbol: AXIN2
  entrez: '8313'
- word: B-Catenin
  symbol: beta-catenin
  source: hgnc_alias_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: SOS
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: TNKS
  symbol: TNKS
  source: hgnc_symbol
  hgnc_symbol: TNKS
  entrez: '8658'
- word: DVL
  symbol: DVL
  source: bioentities_symbol
  hgnc_symbol: DVL1
  entrez: '1855'
- word: DVL
  symbol: DVL
  source: bioentities_symbol
  hgnc_symbol: DVL2
  entrez: '1856'
- word: CK1)
  symbol: CK1
  source: hgnc_alias_symbol
  hgnc_symbol: CSNK1A1
  entrez: '1452'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: B-TrCP
  symbol: betaTrCP
  source: hgnc_alias_symbol
  hgnc_symbol: BTRC
  entrez: '8945'
- word: UPAR
  symbol: UPAR
  source: hgnc_alias_symbol
  hgnc_symbol: PLAUR
  entrez: '5329'
chemicals:
- word: Erlotinib
  source: MESH
  identifier: C400278
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
